Cargando…

Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study

Immunosuppressive treatment is a common cause of cytomegalovirus (CMV) reactivation. However, there is no consensus regarding the risk factors for CMV reactivation in rheumatic diseases. Therefore, this study aimed to elucidate the risk factors associated with CMV reactivation. We retrospectively co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimada, Tatsuya, Higashida-Konishi, Misako, Izumi, Keisuke, Hama, Satoshi, Oshige, Tatsuhiro, Oshima, Hisaji, Okano, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719476/ https://www.ncbi.nlm.nih.gov/pubmed/36463264 http://dx.doi.org/10.1038/s41598-022-25451-4

Ejemplares similares

Allergic disorders and their risk factors in primary Sjögren's syndrome
por: Higashida-Konishi, Misako, et al.
Publicado: (2023)

Dermatomyositis Which Was Double Positive for Anti-MDA5 and Anti-ARS Antibodies That Was Successfully Treated by Intensive Immunosuppressive Therapy
por: Hama, Satoshi, et al.
Publicado: (2022)

Comparing the Clinical and Laboratory Features of Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Seronegative Rheumatoid Arthritis: Stage 1
por: Higashida-Konishi, Misako, et al.
Publicado: (2021)

Comparing the Clinical and Laboratory Features of Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Seronegative Rheumatoid Arthritis
por: Higashida-Konishi, Misako, et al.
Publicado: (2021)

Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study
por: Izumi, Keisuke, et al.
Publicado: (2021)

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study
por: Takahashi, Chihiro, et al.
Publicado: (2017)

Immunosuppressants: COVID-19 and cytomegalovirus reactivation: 2 case reports
Publicado: (2021)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Cytomegalovirus Pneumonia in Patients with Rheumatic Diseases After Immunosuppressive Therapy: A Single Center Study in China
por: Xue, Yu, et al.
Publicado: (2016)

Cutaneous Coinfection of Cytomegalovirus and Mycobacterium chelonae Accelerated by Immunosuppression
por: Tsutsumi, Yutaka, et al.
Publicado: (2021)

Immunosuppressants: COVID-19, Cytomegalovirus reactivation and Pseudomonas infection: 4 case reports
Publicado: (2022)

Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study
por: Lambe, Gaurav, et al.
Publicado: (2022)

The relationship of immunosuppression to cytomegalovirus infection.
por: Dowling, J. N., et al.
Publicado: (1976)

1183. A Prospective Epidemiological & Immunological Study of Cytomegalovirus infection in SLE Patients Receiving Immunosuppressant
por: Autto, Suphanan, et al.
Publicado: (2020)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy
por: Asai, Akira, et al.
Publicado: (2022)

A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants
por: Bruminhent, Jackrapong, et al.
Publicado: (2021)

Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis
por: Kitagawa, Koichi, et al.
Publicado: (2021)

Frequent co-reactivation of Epstein–Barr virus in patients with cytomegalovirus viremia under immunosuppressive therapy and/or chemotherapy
por: Hatayama, Yuki, et al.
Publicado: (2020)

Cytomegalovirus infection in pediatric rheumatic diseases: a review
por: Eisenstein, Eli M, et al.
Publicado: (2010)

The essential role of intestinal microbiota in cytomegalovirus reactivation
por: Kohda, Chikara, et al.
Publicado: (2023)

COVID-19 in rheumatic disease patients on immunosuppressive agents
por: Sharmeen, Saika, et al.
Publicado: (2020)

Cytomegalovirus infection in immunosuppressed patients after kidney transplantation
por: LUSCALOV, SIMONA, et al.
Publicado: (2016)

Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
por: Persaud, Stephen P., et al.
Publicado: (2017)

Cytomegalovirus reactivation in ICU patients
por: Papazian, Laurent, et al.
Publicado: (2015)

Is it safe to vaccinate rheumatic immunosuppressed patients? Yes, of course, but how?
por: Gillet, Pierre
Publicado: (2021)

Cytomegalovirus pneumonia in an immunosuppressed sarcoidosis patient; a rare case of cytomegalovirus infection in a sarcoidosis patient
por: Mozdourian, Mahnaz, et al.
Publicado: (2021)

Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation
por: Nakase, Hiroshi, et al.
Publicado: (2014)

Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments
por: Maillet, François, et al.
Publicado: (2021)

COVID-19 pneumonia, immunosuppression, and cytomegalovirus activation: A perspective
por: Ghosh, K
Publicado: (2021)

Dexamethasone: Cytomegalovirus proctitis following reactivation of cytomegalovirus infection: case report
Publicado: (2021)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Epigenetic Control of Cytomegalovirus Latency and Reactivation
por: Liu, Xue-feng, et al.
Publicado: (2013)

Cytomegalovirus infection in a splenectomized with β‐thalassemia major: immunocompetent or immunosuppressed?
por: Liatsos, George D., et al.
Publicado: (2017)

Immunosuppressants: COVID-19 infection and cytomegalovirus infection: 5 case reports
Publicado: (2021)

Immunosuppressive regimens on conversion of cytomegalovirus infection to disease in liver transplant recipients
por: Rabbani, Amirhassan, et al.
Publicado: (2022)

Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
por: Elsebaey, Mohamed A., et al.
Publicado: (2022)

Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines
por: Etienne, Samuel, et al.
Publicado: (2022)

Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: risk factors and effects of immunosuppressants
por: Henmi, Yujiro, et al.
Publicado: (2018)

Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy—a report of long-term follow-up of serial cases and literature review
por: Xuan, Dandan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fu37p5vsk3a7npq7pv42l61hfv